# US 2016/0238608 A1 · Human cancer-related gene, its encoded products and applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0238608 A1
- Document ID: US20160238608A1
- Status: Published application
- Kind: A1
- Application number: 15/146,307
- Filed: 2016-05-04
- Published: 2016-08-18
- Earliest claimed: 2002-12-24
- Assignees: Peking University
- Applicants: Peking University
- Inventors: Rouli Zhou; Genze Shao; Xinrong Liu; Qingyun Zhang; Jingan Rui; Ye Zhang; Yueying Jin; Ming Lin; Sha Zhang
- Web page: https://patentgrep.com/patent/US20160238608A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/82: Translation products from oncogenes
- C07K 16/30: from tumour cells
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/575: for cancer
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/705: Assays involving receptors, cell surface antigens or cell surface determinants
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention discloses a human cancer-related gene, LAPTM4B, its encoded products and their applications thereof. This human cancer-related gene provided by this invention comprises one of the following nucleotide sequences: (1) SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 6, or SEQ ID No: 8 in the sequence listings; (2) Polynucleotides that encode the protein sequences of SEQ ID No: 4, SEQ ID No: 5, or SEQ ID No: 7 in the sequence listings; (3) DNA sequences having above 90% homology with the DNA sequences specified by SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 6, or SEQ ID No: 8 in the sequence listings, and these DNA sequences encode the proteins with the same or similar functions. This invention enables the developments of new anti-cancer approaches and new anti-cancer medicines. It would create a significant impact on human society.

## Claims

### Claim 1

An in vitro method of detecting cancer or risk of cancer in a human patient, comprising detecting up-regulation of an LAPTM4B protein comprising the amino acid sequence of SEQ ID No: 4 in comparison with the level of said protein in paired non-cancerous and normal tissue, wherein the cancer is hepatocellular carcinoma, stomach cancer, breast cancer, lung cancer or prostate cancer.

### Claim 2 (depends on 1)

A method according to claim 1, wherein an increase in the ratio of the protein LAPTM4B-35 of SEQ ID No: 4 to the protein LAPTM4B-24 of SEQ ID No: 5 is detected.

### Claim 3 (depends on 1)

A method according to claim 1, wherein up-regulation of expression of the protein LAPTM4B-35 of SEQ ID No: 4 is detected.
